CLINICAL STUDY OF TESTICULAR TUMOR AT SHOWA UNIVERSITY SCHOOL OF MEDICINE

• Published in: Journal of The Showa Medical Association Vol. 57; no. 5; pp. 435 - 439
• Main Authors: FUJII, Nobukatsu, SASAKI, Haruaki, GOTO, Ryuta, IKEUCHI, Takao, KAI, Yoshio, ISHIJIMA, Naotaka, MASUYAMA, Tsuneo, INOUE, Katsumi, SAITOU, Toyohiko, YOSHIDA, Hideki
• Format: Journal Article
• Language: Japanese
• Published: The Showa University Society 1997
• Subjects: 10-year survival rate; clinical statistics; testicular tumor
• ISSN: 0037-4342; 2185-0976
• DOI: 10.14930/jsma1939.57.435

A clinical study was conducted of 72 cases of testicular tumor, including 41 treated at the Department of Urology, Showa University School of Medicine Fujigaoka Hospital, and 31 treated at the Department of Urology, Showa University School of Medicine, from 1985 through 1994. The mean age of patients with testicular tumors was 35.2 years. The mean age of those in the seminoma group was 38.5 years and that of patients in the nonseminoma group was 30.8 years. The main complaint was intrascrotal tumor (68 patients, 94.4 %), which was painful in 16 patients (23.5 %) . According to the histological classification, 43 patients (59.7 %) had seminoma and 29 (40.3%) had nonseminoma. By disease stage classif ication, the numbers of patients with seminoma and nonseminoma were 38 and 17, respectively, in stage I, 3 and 1, respectively, in stage II A, 0 and 3, respectively, in stage II B, and 2 and 8, respectively, in stage III. For seminoma in stage I, orchiectomy and radiotherapy were performed in the past, but the number of cases that are placed under observation after orchiectomy has recently increased. In addition to orchiectomy, chemotherapy and radiotherapy or extirpaton of retroperitoneal lymph nodes has been performed as a rule in cases in stage II and above. On the other hand, cases in stage I with nonseminoma were treated with orchiectomy after which chemotherapy, extirpation of retroperitoneal lymph nodes, and radiotherapy were performed. Chemotherapy was done in all cases in stage II and above, followed by extirpation of retroperitoneal lymph nodes and radiotherapy. For chemotherapy, treatment with peplomycin, etoposide, and cisplatin, vinblastine, and bleomycin: and cisplatin and etoposide was done. The 10-year survival rate by clinical stage was 98.5 % overall but was 100 % in the seinoma group. The rate in the nonseminoma group in stages I, II A, and II B was 100 % but was 80.0 % in stage III, indicating a poorer prognosis in the advanced stage.